1. Flanc, R.S., et al., Treatment of diffuse proliferative lupus nephritis: a meta-analysis of randomized controlled trials. Am J Kidney Dis, 2004. 43(2): p. 197-208.
2. Illei, G.G., et al., Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med, 2001. 135(4): p. 248-57.
3. Illei, G.G., et al., Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: long-term followup of a cohort of 145 patients participating in randomized controlled studies. Arthritis Rheum, 2002. 46(4): p. 995-1002.
4. Boumpas, D.T., et al., Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy. Ann Intern Med, 1993. 119(5): p. 366-9.
5. Huong du, L., et al., Risk of ovarian failure and fertility after intravenous cyclophosphamide. A study in 84 patients. J Rheumatol, 2002. 29(12): p. 2571-6.
6. Houssiau, F.A., et al., Short course of weekly low-dose intravenous pulse cyclophosphamide in the treatment of lupus nephritis: a preliminary study. Lupus, 1991. 1(1): p. 31-5.
7. Sollinger, H.W., Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. Transplantation, 1995. 60(3): p. 225-32.
8. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. European Mycophenolate Mofetil Cooperative Study Group. Lancet, 1995. 345(8961): p. 1321-5.
9. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. Transplantation, 1996. 61(7): p. 1029-37.
10. Budde, K., et al., Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: results of a 1-year study. Am J Transplant, 2004. 4(2): p. 237-43.
11. Salvadori, M., et al., Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients. Am J Transplant, 2004. 4(2): p. 231-6.
12. Allison, A.C., et al., In vitro immunosuppressive effects of mycophenolic acid and an ester pro-drug, RS-61443. Transplant Proc, 1991. 23(2 Suppl 2): p. 10-4.
13. Allison, A.C. and E.M. Eugui, Mechanisms of action of mycophenolate mofetil in preventing acute and chronic allograft rejection. Transplantation, 2005. 80(2 Suppl): p. S181-90.
14. Corna, D., et al., Mycophenolate mofetil limits renal damage and prolongs life in murine lupus autoimmune disease. Kidney Int, 1997. 51(5): p. 1583-9.
15. Dooley, M.A., et al., Mycophenolate mofetil therapy in lupus nephritis: clinical observations. J Am Soc Nephrol, 1999. 10(4): p. 833-9.
16. Gaubitz, M., et al., Mycophenolate mofetil for the treatment of systemic lupus erythematosus: an open pilot trial. Lupus, 1999. 8(9): p. 731-6.
17. Glicklich, D. and A. Acharya, Mycophenolate mofetil therapy for lupus nephritis refractory to intravenous cyclophosphamide. Am J Kidney Dis, 1998. 32(2): p. 318-22.
18. Briggs, W.A., M.J. Choi, and P.J. Scheel, Jr., Successful mycophenolate mofetil treatment of glomerular disease. Am J Kidney Dis, 1998. 31(2): p. 213-7.
19. Kingdon, E.J., et al., The safety and efficacy of MMF in lupus nephritis: a pilot study. Lupus, 2001. 10(9): p. 606-11.
20. Pisoni, C.N., et al., Mycophenolate mofetil in systemic lupus erythematosus: efficacy and tolerability in 86 patients. J Rheumatol, 2005. 32(6): p. 1047-52.
21. Riskalla, M.M., et al., Tolerability of mycophenolate mofetil in patients with systemic lupus erythematosus. J Rheumatol, 2003. 30(7): p. 1508-12.
22. Chan, T.M., et al., Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med, 2000. 343(16): p. 1156-62.
23. Chan, T.M., Lupus nephritis: induction therapy. Lupus, 2005. 14 Suppl 1: p. s27-32.
24. Li, L., et al., Mycophenolate mofetil treatment for diffuse proliferative lupus nephritis: a multicenter clinical trial in China. Zhonghua Nei Ke Za Zhi, 2002. 41(7): p. 476-9.
25. Ginzler, E.M., et al., Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med, 2005. 353(21): p. 2219-28.
26. Contreras, G., et al., Sequential therapies for proliferative lupus nephritis. N Engl J Med, 2004. 350(10): p. 971-80.
27. Alba, P., M.Y. Karim, and B.J. Hunt, Mycophenolate mofetil as a treatment for autoimmune haemolytic anaemia in patients with systemic lupus erythematosus and antiphospholipid syndrome. Lupus, 2003. 12(8): p. 633-5.
28. Chang, H.K., Successful treatment of refractory thrombocytopenia with mycophenolate mofetil in a patient with systemic lupus erythematosus. J Korean Med Sci, 2005. 20(5): p. 883-5.
29. Mak, A. and C.C. Mok, Mycophenolate mofetil for refractory haemolytic anemia in systemic lupus erythematosus. Lupus, 2005. 14(10): p. 856-8.
30. Pisoni, C.N., et al., Skin manifestations of systemic lupus erythematosus refractory to multiple treatment modalities: poor results with mycophenolate mofetil. Clin Exp Rheumatol, 2005. 23(3): p. 393-6.
31. Schanz, S., et al., Successful treatment of subacute cutaneous lupus erythematosus with mycophenolate mofetil. Br J Dermatol, 2002. 147(1): p. 174-8.
32. Vasoo, S., J. Thumboo, and K.Y. Fong, Refractory immune thrombocytopenia in systemic lupus erythematosus: response to mycophenolate mofetil. Lupus, 2003. 12(8): p. 630-2.
33. Karim, M.Y., et al., Mycophenolate mofetil for systemic lupus erythematosus refractory to other immunosuppressive agents. Rheumatology (Oxford), 2002. 41(8): p. 876-82.
34. Bijl, M., et al., Mycophenolate mofetil prevents a clinical relapse in patients with systemic lupus erythematosus at risk. Ann Rheum Dis, 2003. 62(6): p. 534-9.